Extreme prematurity is the leading cause of death among children under 5 years of age. Currently, there is no treatment for bronchopulmonary dysplasia (BPD), the most common complication of extreme prematurity. Experimental studies in animal models of BPD suggest that mesenchymal stromal cells (MSCs) are lung protective. To date, no systematic review and meta-analysis has evaluated the preclinical evidence of this promising therapy. Our protocol was registered with Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies prior to searching MEDLINE (1946 to June 1, 2015, Embase (1947 to 2015 , Pubmed, Web of Science, and conference proceedings (1990 to present) for controlled comparative studies of neonatal animal models that received MSCs or cell free MSC-derived conditioned media (MSC-CM). Lung alveolarization was the primary outcome. We used random effects models for data analysis and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. We screened 990 citations; 25 met inclusion criteria. All used hyperoxia-exposed neonatal rodents to model BPD. MSCs significantly improved alveolarization (Standardized mean difference of 21.330, 95% confidence interval [CI 21.724, 20.94, I 2 69%]), irrespective of timing of treatment, source, dose, or route of administration. MSCs also significantly ameliorated pulmonary hypertension, lung inflammation, fibrosis, angiogenesis, and apoptosis. Similarly, MSC-CM significantly improved alveolarization, angiogenesis, and pulmonary artery remodeling. MSCs, tested exclusively in hyperoxic rodent models of BPD, show significant therapeutic benefit. Unclear risk of bias and incomplete reporting in the primary studies highlights nonadherence to reporting standards. Overall, safety and efficacy in other species/large animal models may provide useful information for guiding the design of clinical trials. STEM CELLS
INTRODUCTION
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation). Preterm birth has surpassed infectious diseases as the number one cause of under-5 mortality in children [1] . The most common complication of extreme preterm birth is bronchopulmonary dysplasia (BPD), a chronic lung disease [2] that complicates the course of approximately 40% of infants born <28 weeks gestation [3, 4] . BPD is strongly predictive of late death or disability [5, 6] and has a high economic burden [7] . Despite improvements in perinatal care, the incidence of BPD has increased over the last decade. BPD is a multifactorial disease in which extreme preterm birth, perinatal inflammation, mechanical ventilation, and oxidative stress contribute to impaired lung growth [8] .
Survival of more immature infants born during the canalicular and saccular stages of lung development disrupt the normal program of alveolar and vascular development, resulting in alveolar simplification, dysmorphic capillaries, and remodeling of the vascular and airway smooth muscle layer [9] . Consequently, prevention of lung injury in ever more prematurely born infants has become increasingly challenging.
Although, many pharmacological and nonpharmacological approaches have been tested for the prevention and treatment of BPD, only few have contributed modestly in decreasing the incidence/severity of BPD [10] . Postnatal systemic corticosteroids remain controversial because of their association with adverse neurodevelopmental outcomes [11] .
Recent insights into stem cell biology have unraveled the therapeutic potential of stem cells. Stem cells can self-renew and differentiate into specialized cell types thereby promoting organogenesis, tissue regeneration, maintenance, and repair [12] . Mesenchymal stromal cells (MSCs) attracted particular interest because of their ease of isolation, expansion, apparent multipotency, and pleiotropic effects in various injury models [13] . In experimental neonatal lung injury, MSCs are lung protective and exert their therapeutic benefit mainly through a paracrine activity [14] . These data suggest MSCs as a promising therapy to reduce the incidence/severity of BPD in extreme premature infants.
To date, there has been no systematic review and/or metaanalysis on the therapeutic potential of MSC in experimental BPD. Translation of potentially life-saving therapies is unacceptably slow. Even more concerning is overall failure, with less than 5% of high impact preclinical reports being clinically translated and only 11% of clinically tested agents ultimately receiving licensing [15] . In a first step to ensure the evidence-based translation of this promising MSC therapy into the clinic for patients at risk of developing BPD, we have performed this systematic review to assess the current evidence to help guide the design of clinical trials.
MATERIALS AND METHODS

Protocol
The protocol, developed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-P checklist [16] was prospectively registered and is available on the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies website (CAMARADES) [17] . We followed the PRISMA [18] guidelines for this manuscript.
Inclusion and Exclusion Criteria
We included preclinical, controlled comparative studies of neonatal animal models mimicking features observed in human BPD and evaluated the therapeutic potential and safety of MSCs or cell free MSC-derived conditioned media. MSCs were defined using the minimal criteria set out in the International Society for Cellular Therapy (ISCT) [19] consensus statement. Noninterventional studies, studies without controls, and non-neonatal models of lung injury were excluded.
Search Strategy and Selection Criteria
In brief, MEDLINE including In-process and other Non-Indexed Citations (1946 to June 1, 2015) , EMBASE (1947 to 2015 using the Ovid interface and Science Citation Index Expanded (SCI-EXPANDED), and Conference Proceedings Citation Index- Science, 1990 to present using the Web of Science were searched, without language restrictions, for the search term "mesenchymal stromal cells," "bronchopulmonary dysplasia," and "animals".
Primary and Secondary Outcomes
Our primary outcome was lung alveolarization on histology. Secondary outcomes included lung inflammation, pulmonary hypertension, pulmonary artery remodeling, pulmonary vascular density, lung fibrosis, oxidative stress, lung function, exercise capacity, safety, weight gain, long-term outcome, and survival.
Risk of Bias and Study Validity
Risk of bias was assessed by two reviewers (S.A., M.A.), for each included study, using SYRCLE's Risk of Bias tool (an adaptation of Cochrane Risk of Bias tool) for animal studies [23] . We extracted study characteristics that were related to the construct and external validity [24] . For construct validity, we included: age, sex, strain and animal species, comorbidities, type of BPD model, timing, dose and mode of MSC administration, and the use of any cointerventions.
Data Analysis
Data were analyzed with OpenMetaAnalyst. We calculated standard deviations from standard errors and n values. For continuous data, we used standardized mean difference because different measurements scales were reported for the same outcomes. We used DerSimonian and Laird random-effects meta-analysis model to account for heterogeneity (i.e., both within and between study variance) [25] . The unit of analysis for the meta-analyses were the individual extracted experiments. For dichotomous data (mortality) we calculated odd ratios. We assessed statistical heterogeneity with the I 2 statistic with 95% confidence intervals, and data were visualized using forest plots. Statistical heterogeneity was assessed as very low (0%-25%), low (25%-50%), moderate (50%-75%), and high (>75%) using the I-statistic [25] . We assessed for publication bias using a funnel plot and adjusted our results for it using the trim and fill method (Comprehensive Meta-Analysis) [26] .
We performed prespecified subgroup analyses to examine heterogeneity of the treatment of MSCs on alveolarization where there was sufficient data reported. The prespecified subgroups included pairwise meta-analyses based on: MSC dose, route of injection, source of MSCs, timing of treatment post-natal, and timing of assessment post-natal.
Effect size was interpreted based on Cohen's d as small effect (0.2), medium effect (0.5), and large effect size (0.8) [27] .
RESULTS
Study Characteristics
In total, 1,121 records were identified ( Fig. 1) and duplicate references were removed, resulting in 990 records for screening. Preliminary screening excluded 930 records. Sixty records were further examined by reviewing the full text articles where, based on our eligibility criteria, a further 35 papers were excluded leaving 25 included studies (Fig. 1) . Two studies were excluded post hoc because the outcomes did not meet inclusion criteria. One study described Bronchoalveolar stem cell number in response to MSC treatment [53] ; the other study used surfactant protein-C expression as endpoint [54] .
Rodents exposed to hyperoxia were the exclusive animal BPD model ( 29, 31, 32, 34, 40, 51] , and less than one-third (30%, n 5 10) used high dose [34, 35, 38, 39, 41] . Fifty-eight percent (n 5 19) used intratracheal route of administration [28, 29, 31-34, 40, 41, 47] , while 12% (n 5 4) used intranasal [35, 38] and 15% (n 5 5) each used intraperitoneal [34, 38, 43, 46, 51] and intravenous routes (Table 2) [30, 39, 42, 52] .
Lung alveolarization in rodents starts on postnatal day 5 (P5). Hence timing of treatment was subdivided, a priori, into Prevention (P5) and Rescue (>P5). Also, timing of assessment was subdivided into Early (P14), Mid (>P14 to P28), and Late (>P28). 
Risk of Bias Assessments
Risk of Bias was assessed for the primary outcome of alveolarization in 25 included studies using 11 domains (see Table 3 Fig. 2A ). Funnel plot analysis revealed asymmetry suggesting potential missing studies. Subsequent trim and fill analysis resulted in the addition of six imputed experiments and a small reduction in estimated effect size (-1.19), 95% CI (-1.62, 20.72) (Fig. 3) .
Treatment effect was further examined in pre-specified subgroups for dose ( (Fig. 4) . In all subgroups, the treatment effect favored MSCs compared with controls with the exception of the intranasal route (SMD 0.28, 95% CI [-0.43, 1.00], I 2 66), which was dominated by three experiments from one study. We noted that Bone marrow MSCs were more commonly used than umbilical cord. Although both sources showed similar statistically significant large effect size, there was high heterogeneity in the former group and moderate in the latter ( (Fig. 4) . Again, the heterogeneity ranged from moderate to high. 
Meta-Analysis for Secondary Outcomes
Lung Inflammation. Fig. 2A) .
Conditioned Media. MSC-Conditioned media did not improve pulmonary hypertension (p 5 .07) [30, 37, 40, 41, 48] 
Lung Fibrosis
MSCs. MSC reduced lung fibrosis with a large effect size (p < .01), SMD 22.55, 95% CI (-3.95, 21.14) compared with controls, with high heterogeneity (I 2 80%) [32-34, 49, 52] (Supporting Information Fig. 3 ).
Conditioned Media. Hansmann et al. [37] found a 50% decrease in alveolar septal collagen deposition when compared with hyperoxia-exposed/Mouse Lung Fibroblast-conditioned media-treated animals. Conditioned Media. We did not find any studies using conditioned media for this outcome.
Lung Angiogenesis
Pulmonary Artery Remodeling
MSCs. One study [30] found that hyperoxia-induced muscularization of intrapulmonary arterioles decreased significantly with Bone marrow derived MSC treatment compared with the PBS-injected controls.
Conditioned Media. MSC-conditioned media resulted in a large effect size (p < .01) on pulmonary artery remodeling [30, 37, 40, 48] Fig. 6 ).
Lung Function
MSCs. Liu et al. [38] reported a significant dose-dependent effect of intraperitoneal MSC in restoring total lung capacity, inspiratory capacity, compliance, elastance, and area of PV loop while having no effect on airway resistance. In contrast, intranasal MSC had no obvious effect on lung function. Pierro et al. [40] found that MSC prevented the decrease in lung compliance when given at postnatal day 4.
Conditioned Media. Hansmann et al. [37] reported complete reversal of airway hyper responsiveness to inhaled methacholine and restoration of dynamic lung compliance. Pierro et al. [40] reported that conditioned media prevented and restored significant deterioration in lung compliance.
Oxidative Stress
MSC. Three experiments from two studies [32, 33] Fig. 7 )
Conditioned Media. We did not find any studies using conditioned media for the outcome of oxidative stress.
Exercise Capacity
MSC. Only two studies [40, 47] looked at exercise capacity as a result of use of MSCs in preclinical BPD. Van Haaften et al. [47] found improved exercise tolerance in both Prevention (P4) and Rescue (P14) experiments. However, it was unclear as to when the assessment was done. Pierro et al. [40] found a similar benefit at 6 months when a hyperoxic BPD model was preventively treated with MSC on P4 compared with hyperoxic controls.
Conditioned Media. Pierro et al. [40] reported improved exercise capacity 6 months following treatment with MSC derived conditioned media.
Survival
MSCs. Fig. 8 ).
Conditioned Media. We did not find any studies reporting on this outcome.
Safety
Ahn et al. [28] and Pierro et al. [40] were the only studies which reported on safety. While the former examined hypertrophy, tumor, hemorrhage and hematoma by histopathology in brain, heart, lung, liver, and spleen on postnatal day 70, the latter study looked at tumor formation at 6 months by whole body CT scan. Both studies did not report any adverse events.
DISCUSSION
Our systematic review shows that MSCs in preclinical hyperoxic rodent models of BPD resulted in a statistically significant large treatment effect (Cohen's d 0.8) for the primary outcome of lung alveolarization and secondary outcomes, including inflammation, pulmonary hypertension, lung fibrosis, apoptosis, and lung angiogenesis. Likewise, MSC-derived conditioned media conferred therapeutic benefit for alveolarization, pulmonary artery remodeling, and angiogenesis.
Internal and External Validity
First, we found potential publication bias for our primary outcome. The Trim and Fill statistical adjustment resulted in a minor reduction in the treatment effect although this effect remained statistically significant and clinically important. Regardless, the high prevalence of publication bias in animal research and inflation of effect sizes is a cause for concern, which could potentially bias conclusions [55] . Furthermore, our analyses revealed that poor reporting was prevalent. None of the 25 studies met the criteria for "low risk of bias." While almost three quarters of the included studies mentioned randomization, there was no attempt made to report the important specifics about sequence generation or allocation concealment. Similarly, the reporting of other fundamental information, such as sample size calculation, was also lacking. This appears to be consistent with other studies in animal research [56, 57] and stem cell research is no exception. In all likelihood, such auxiliary data exist yet remaining unpublished, thereby making it challenging to precisely replicate and validate these experiments and encourage a robust understanding and characterization of evolving stem cell research [58] . Notwithstanding the existence of ARRIVE guidelines on reporting standards, we found many key aspects largely ignored, calling for rigorous enforcement of these guideline [59] . (Supporting Information  Table 1 ; Supporting Information Fig. 9 ) Second, we found a moderate to high degree of heterogeneity in our meta-analyses. Although this is not uncommon in animal studies-given their diversity of species, heterogeneous design, intervention protocols, and different outcomes [60] Information Table 2 ). Hence, there is a need for standardization of oxygen concentration and duration of oxygen exposure for induction of lung injury in future preclinical studies. Also, it is our speculation that the heterogeneity between dosages of MSCs could be potentially diminished by standardization of dose by indexing it to the body weight.
Implications for Research
To the best of our knowledge, this is the first systematic review using quantitative methods (i.e., meta-analyses) examining the therapeutic potential of MSCs and MSC-conditioned media in preclinical models of BPD. The study is timely considering the fact that MSCs are currently being tested in numerous clinical trials for their safety and therapeutic potential for regenerative purposes including neonatal diseases in an effort toward evidence generation as mandated by the Food and Drug administration (FDA). However, the value of the promising preclinical data should be treated with caution, because of the historic failure of apparently exciting therapies in animal models to translate from the bench to the clinic, partly related to some short-comings in the design and reporting of preclinical studies [61] .
Rodents were the only animal model of BPD found in our systematic review. Clearly rodents are a well-established model, with lungs in the late canalicular/early saccular stage, equivalent to the lung developmental stage of extreme preterm infants, providing excellent insights into lung developmental events [62] . Nonetheless, the disparity between rodent and human physiology remains so great that the direct translation to clinical trials may fall short. It may, therefore, be imperative that other species or newer models that more closely resemble human biology be explored to bridge the translational gap to clinical trials. Larger and arguably better animal models of BPD exist, such as the preterm lamb [63] and nonhuman primate models [64] . We speculate that the high costs and ethical considerations with these models might have precluded them from preclinical studies of MSCs in BPD so far. Indeed, as with studies in stroke, the effect size may diminish as different animal models representing different clinical characteristics and comorbidities are explored [65] . Hence there is a need for multi-species testing in preclinical BPD to ensure that the promising results from the rodent model can be translated to humans before commencing expensive and protracted clinical trials. Large animal models have played a pivotal role in dispelling safety concerns from regulatory agencies and establishing pharmacokinetics and pharmacodynamics with novel therapeutic agents in adult regenerative medicine [66] .
Implications for Clinical Trials
MSCs in small animal models have lent a thorough understanding of the therapeutic mechanism in preclinical BPD thereby setting the stage for multiple ongoing early clinical trials. MSCs are potent immune modulatory cells capable of decreasing inflammation in experimental BPD (Supporting Information Figure 1 ). Even though there was no difference in effect size between timing of intervention, the main mechanism of action of MSCs would imply clinical benefit during the inflammatory phase of BPD, the period when postnatal steroids are being carefully considered around 10 to 21 days of age in current clinical practice. It is difficult to answer this question based on preclinical studies in rodents. Another limitation of this model is the ability to explore whether a single or repeated injections may yield superior benefit. The first phase I trial was designed to administer MSCs after the first week of life [67] .
Interestingly, our systematic review suggests a larger effect size of intravenous versus intratracheal administration of MSCs, although this was not adjusted for cell dose and only one study directly compared these two routes of administrations. Since the advent of surfactant and inhaled nitric oxide, neonatologists are comfortable with airway delivery of medications. Local administration may confine the therapeutic effect to the lung and reduce potential adverse effects to other organs. Logistical aspects also need to be taken into account for clinical trial design including the timing of administration and whether an endotracheal tube is still in place at this time. The phase I trial in BPD used the intratracheal route while a phase I trial for Acute Respiratory Distress Syndrome administered MSC intravenously [68] Carefully designed animal studies in other species and models as well as clinical trials will need to address the magnitude of differential therapeutic effects between intravenous versus intratracheal administration of MSCs.
The heterogeneity of effect size in the low and high dose group highlights the need for dose-escalation design in early phase clinical trials [67, 68] to detect the safest effective dosing regimen.
Finally, our systematic review was not able to provide guidance for clinical trial design on a crucial aspect specific to cellbased therapies: the manufacturing process and thus quality of the MSC product [69] . With regard to cell source, perinatal tissue (including placenta, umbilical cord, and cord blood) appears as the clinically more relevant source for the treatment of neonatal diseases and may provide MSCs with greater repair potential than older adult sources (bone marrow, adipose tissue) [70] although this requires more investigations. Preclinical studies analyzed in our systematic review used mostly bone marrow-derived MSCs (n 5 17) compared with perinatal sources (umbilical cord blood, n 5 6; Wharton Jelly n 5 2), and no difference in therapeutic benefit were found. However, knowing that even small variation in the processing methods (enzymatic digestion, plating density, culture media and devices, supplements or growth factors, oxygen concentration, passage number, cryopreservation method, fresh vs. cryopreserved product) may change the efficacy of the final MSC product [48] reporting of these crucial parameters should be mandatory to allow appropriate interpretation of the results to provide useful guidance for clinical trial design.
The strengths of our systematic review include a rigorous peer reviewed search strategy in accordance with the PRESS standards [20] and use of international guidance and standards to conduct our systematic review and meta-analysis. However, our review was also limited by the fact that we did not perform an updated search as we had registered a protocol on CAMARADES website for an expanded review of all cell types [71] . Also, a large number of published data were available only in the form of figures and not in an easily extractable numerical form. Almost all the data were extracted from the figures in the published article using an open source program that can work with a variety of plot types and images. Minor distortion of data is possible but all groups would be equally affected. Wiley Periodicals, Inc. on behalf of AlphaMed Press hyperoxic models of BPD in rodents resulted in statistically significant improvement in lung injury. Although this may be true in rodents, there is a need to explore this effect in different animal models and species. Overall, we noted unclear risk of bias and incomplete reporting in the primary studies. This review highlights methodological flaws and other knowledge gaps to guide clinical trial design suggesting a need to implement reporting standards such as the ARRIVE guidelines to bring more rigor in the design of preclinical studies and ultimately ensure timely, safe and effective translation of discoveries into patients.
